Why Aurora Cannabis (TSX:ACB) Gained 42%

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) soars after reporting improved results, but there are still plenty of headwinds ahead.

| More on:
edit Jars of marijuana

Image source: Getty Images

Leading Canadian cannabis stock Aurora Cannabis (TSX:ACB)(NYSE:ACB) gained a startling 42% in a week. This sharp gain, which is greater than many stocks deliver in one year, underscores the considerable volatility of marijuana stocks. Even after that rally, Aurora is still down by a whopping 54% for the year to date — that’s almost double the 30% decline of the industry’s largest ETF ETFMG Alternative Harvest ETF.

There are still headwinds ahead for Aurora, indicating that it’s not as appealing as some investors believe.

Aurora’s improved results

Aurora’s latest fiscal third quarter 2020 results are responsible for fueling the sudden spike in value. Investors reacted positively to the numbers sparking claims that the worst is over for the beleaguered cultivator.

Aurora’s net revenue shot up 35% compared to the previous quarter, most of which was driven by a 125% spike in international medical cannabis revenue.

Notably, adjusted EBITDA shot-up by 37% to a little less than negative $51 million.

These improved numbers can be attributed to a 34% quarter over quarter increase in cannabis sold to 12,729 kilograms. Aurora is a low cost cultivator reporting cash costs of $0.85 per gram produced, which was $0.03 per gram lower than the previous quarter.

For these reasons, it’s easy to understand the considerable enthusiasm which has buoyed Aurora’s stock.

While those numbers certainly represent a solid improvement for the beaten down cannabis stock, Aurora doesn’t deserve accolades from investors yet. The company is still bleeding red ink, reporting a $137 million third quarter loss, which, while lower than the $1.3 billion reported for the previous quarter, shows that Aurora is burning through cash.

Poor outlook for cannabis stocks

It is difficult to see Aurora becoming profitable anytime soon. The global legal cannabis market is not shaping up to be as big as industry pundits initially believed. Claims of up to US$500 billion appear preposterous, particularly with many analysts reducing their forecasts.

Grandview Research’s claim of a US$74 billion global legal marijuana market is unrealistic with some analysts predicting it could be as low as US$40 billion.

The rapid easing of marijuana laws, expected after Canada became the first developed nation to legalize recreational consumption, is not occurring. The stigma associated with marijuana’s use and concerns over health impacts, notably hospital admissions and vehicular accidents spiking in jurisdictions where social use is legal, are weighing on law makers.

The coronavirus pandemic, aside from causing forcing dispensaries to close in many jurisdictions, is distracting legislators from the legalization of marijuana.

The economic fallout from the pandemic has effectively made it impossible for cannabis companies to access credit, in an industry already starved of capital. Banks and other financial institutions are winding down lending activities and bulking up their cash reserves in response to an anticipated spike in credit losses.

That is bad news for cannabis companies like Aurora which are burning through cash at a furious pace.

Aurora’s weak financial position a concern

Despite highly dilutive equity raisings earlier this year, Aurora only had $230 million in cash on its balance sheet at the end of the third quarter. That is equivalent to around two quarters of losses based on the latest results. It is also $74 million greater than the almost $156 million drawn on Aurora’s credit facility maturing in August 2021.

More worrying is the inflated goodwill on Aurora’s balance sheet. Even after the previous quarter’s sizable write-downs, including $921 million for goodwill and intangible assets, Aurora still has a whopping $2.4 billion of goodwill on its balance sheet plus $500 million of intangible assets.

Goodwill and intangible assets compose an unbelievable 62% of Aurora’s assets. They are also an incredible three-times its market cap and more than double Aurora’s enterprise value. In an unproven industry facing considerable headwinds, this indicates there will be further write-downs and impairment charges.

Foolish takeaway

After a difficult year, Aurora’s current results offer a glimmer of hope for beleaguered investors. The ballooning optimism surrounding the cultivators outlook appear overbaked. There are certainly more asset write-downs and dilutive capital raising ahead.

Growing industry headwinds, overpriced assets and a lack of profitability makes Aurora an unattractive investment, even after the latest results.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Matt Smith has no position in any of the stocks mentioned.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Here’s Why it’s Not Too Late to Buy Cronos Group Stock

The optimism about U.S. federal marijuana legalization and its anticipation are potent bullish triggers for the Canadian cannabis industry.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Canopy Growth Stock Is on a Tear: Is it a Good Buy Now? 

Canopy Growth (TSX:WEED) stock surged by 80% from news out of the U.S., but is enough there without the news…

Read more »